论文部分内容阅读
目的:调查了解某院冠状动脉粥样硬化性心脏病(以下简称“冠心病”)患者口服抗血小板药物治疗情况,进一步规范医院抗血小板治疗的应用。方法:回顾性调查2015年8月1日—2016年7月31日于某院心血管内科住院的冠心病患者共832例,统计患者基本情况、既往病史、冠心病类型、口服抗血小板药物应用情况和药物品种数发生调整的原因等。结果:冠心病患者出院时口服抗血小板药物治疗品种数发生调整的情况主要为减少抗血小板药物品种数(占比99.14%),用药品种数减少的主要原因为患者/家属用药依从性差(102例,占比43.22%),其次为患者具有极高出血风险(55例,占比23.30%)和高出血风险(48例,占比20.34%)。结论:患者/家属用药依从性差和对出血风险的过度担心制约着冠心病患者的规范化抗血小板治疗,临床药师应合理利用药物治疗数据来开展更具针对性的药学服务,确保患者安全有效的应用抗血小板药物。
Objective: To investigate the oral antiplatelet therapy in patients with coronary atherosclerotic heart disease (hereinafter referred to as “coronary heart disease”) in a hospital and to further standardize the application of antiplatelet therapy in the hospital. Methods: A total of 832 coronary heart disease patients admitted to a hospital from August 1, 2015 to July 31, 2016 were retrospectively reviewed. The basic information, past medical history, type of coronary heart disease, application of oral antiplatelet drugs The situation and the reasons for the adjustment of drug varieties. Results: At the time of discharge from hospital, patients taking oral antiplatelet drugs were adjusted to reduce the number of antiplatelet drugs (accounting for 99.14%). The main reason for the decrease in the number of drug users was poor compliance with medication (102 cases , Accounting for 43.22%), followed by patients with high risk of bleeding (55 cases, accounting for 23.30%) and high bleeding risk (48 cases, accounting for 20.34%). CONCLUSIONS: Poor compliance of patients and their families and over-fearing of bleeding risk restrict the standardized anti-platelet therapy in patients with coronary heart disease. Clinical pharmacists should make rational use of drug treatment data to conduct more targeted pharmacy services and ensure the safe and effective use of the patients Anti-platelet drugs.